United Therapeutics Corporation

NasdaqGS:UTHR Rapporto sulle azioni

Cap. di mercato: US$16.6b

United Therapeutics Gestione

Gestione criteri di controllo 2/4

United Therapeutics Il CEO è Martine Rothblatt, nominato in Jan1996, e ha un mandato di 28.83 anni. la retribuzione annua totale è $ 16.96M, composta da 8.7% di stipendio e 91.3% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 1.49% delle azioni della società, per un valore di $ 248.65M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 15.6 anni e 22.2 anni.

Informazioni chiave

Martine Rothblatt

Amministratore delegato

US$17.0m

Compenso totale

Percentuale dello stipendio del CEO8.7%
Mandato del CEO28.8yrs
Proprietà del CEO1.5%
Durata media del management15.6yrs
Durata media del Consiglio di amministrazione22.2yrs

Aggiornamenti recenti sulla gestione

Recent updates

United Therapeutics: One To Believe In Despite Competitive Threats

Nov 14

Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?

Oct 18
Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?

Benign Growth For United Therapeutics Corporation (NASDAQ:UTHR) Underpins Its Share Price

Sep 27
Benign Growth For United Therapeutics Corporation (NASDAQ:UTHR) Underpins Its Share Price

United Therapeutics: Economics Support Compounding Ability

Aug 20

With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case

Jul 26
With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case

United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet

Jul 04
United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet

United Therapeutics Corporation's (NASDAQ:UTHR) Business And Shares Still Trailing The Market

Jun 13
United Therapeutics Corporation's (NASDAQ:UTHR) Business And Shares Still Trailing The Market

United Therapeutics: Exciting Company With A Big Problem

Jun 02

We Ran A Stock Scan For Earnings Growth And United Therapeutics (NASDAQ:UTHR) Passed With Ease

Apr 05
We Ran A Stock Scan For Earnings Growth And United Therapeutics (NASDAQ:UTHR) Passed With Ease

United Therapeutics: Neutral Stance On Tyvaso's Patent Challenges And Future Growth Prospects

Mar 20

Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?

Mar 15
Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?

Investors Aren't Entirely Convinced By United Therapeutics Corporation's (NASDAQ:UTHR) Earnings

Jan 02
Investors Aren't Entirely Convinced By United Therapeutics Corporation's (NASDAQ:UTHR) Earnings

United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly

Dec 08
United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly

Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today

Nov 16
Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today

United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet

Sep 04
United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet

Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today

Aug 07
Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today

United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly

May 22
United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly

Does United Therapeutics (NASDAQ:UTHR) Deserve A Spot On Your Watchlist?

Apr 25
Does United Therapeutics (NASDAQ:UTHR) Deserve A Spot On Your Watchlist?

We Think United Therapeutics (NASDAQ:UTHR) Can Manage Its Debt With Ease

Feb 06
We Think United Therapeutics (NASDAQ:UTHR) Can Manage Its Debt With Ease

With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case

Jan 16
With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case

Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?

Oct 20
Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?

United Therapeutics: Ability To Expand Tyvaso To Large IPF Market

Aug 24

Do United Therapeutics' (NASDAQ:UTHR) Earnings Warrant Your Attention?

Aug 04
Do United Therapeutics' (NASDAQ:UTHR) Earnings Warrant Your Attention?

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Martine Rothblatt rispetto agli utili di United Therapeutics?
DataCompenso totaleStipendioGuadagni aziendali
Sep 30 2024n/an/a

US$1b

Jun 30 2024n/an/a

US$1b

Mar 31 2024n/an/a

US$1b

Dec 31 2023US$17mUS$1m

US$985m

Sep 30 2023n/an/a

US$900m

Jun 30 2023n/an/a

US$872m

Mar 31 2023n/an/a

US$728m

Dec 31 2022US$5mUS$1m

US$727m

Sep 30 2022n/an/a

US$707m

Jun 30 2022n/an/a

US$631m

Mar 31 2022n/an/a

US$687m

Dec 31 2021US$4mUS$1m

US$476m

Sep 30 2021n/an/a

US$462m

Jun 30 2021n/an/a

US$471m

Mar 31 2021n/an/a

US$405m

Dec 31 2020US$5mUS$1m

US$515m

Sep 30 2020n/an/a

US$469m

Jun 30 2020n/an/a

US$430m

Mar 31 2020n/an/a

US$528m

Dec 31 2019US$46mUS$1m

-US$104m

Sep 30 2019n/an/a

-US$92m

Jun 30 2019n/an/a

-US$118m

Mar 31 2019n/an/a

-US$150m

Dec 31 2018US$16mUS$1m

US$589m

Sep 30 2018n/an/a

US$543m

Jun 30 2018n/an/a

US$713m

Mar 31 2018n/an/a

US$484m

Dec 31 2017US$37mUS$1m

US$418m

Compensazione vs Mercato: La retribuzione totale di Martine ($USD 16.96M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 12.66M ).

Compensazione vs guadagni: La retribuzione di Martine è aumentata di oltre il 20% nell'ultimo anno.


AMMINISTRATORE DELEGATO

Martine Rothblatt (69 yo)

28.8yrs

Mandato

US$16,958,057

Compensazione

Dr. Martine A. Rothblatt, Ph D., J.D., M.B.A., founded United Therapeutics Corporation in 1996 and has been its Chief Executive Officer since June 26, 2016 and as its Chairman since 1996. Dr. Rothblatt ser...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Martine Rothblatt
Founder28.8yrsUS$16.96m1.49%
$ 248.7m
Michael Benkowitz
President & COO8.4yrsUS$9.81m0.0058%
$ 960.6k
James Edgemond
CFO & Treasurer11.8yrsUS$6.05m0.018%
$ 3.0m
Paul Mahon
Executive VP28.8yrsUS$5.15m0.082%
$ 13.7m
Dewey Steadman
Head of Investor Relationsno dataNessun datoNessun dato
Holly Hobson
Associate Vice President of Human Resourcesno dataNessun datoNessun dato
Kevin Gray
Senior Vice President of Strategic Operations & Logisticsno dataNessun datoNessun dato
Patrick Poisson
Executive VP of Technical Operations15.6yrsNessun datoNessun dato
Leigh Peterson
Executive Vice President of Product Development & Xenotransplantationno dataNessun datoNessun dato
Gil Golden
Senior VP & Chief Medical Officerno dataNessun datoNessun dato

15.6yrs

Durata media

56yo

Età media

Gestione esperta: Il team dirigenziale di UTHR è esperto e expertise (durata media dell'incarico 15.6 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Martine Rothblatt
Founder28.8yrsUS$16.96m1.49%
$ 248.7m
Samuel Thier
Member of the Scientific Advisory Boardno dataNessun datoNessun dato
Raymond Kurzweil
Independent Director22.8yrsUS$457.60k0.027%
$ 4.5m
Louis Sullivan
Independent Director & Member of the Scientific Advisory Board22.2yrsUS$471.54k0.029%
$ 4.9m
Raymond Dwek
Independent Director & Member of the Scientific Advisory Board22.8yrsUS$456.54k0.0039%
$ 652.6k
Christopher Patusky
Independent Vice Chairman & Lead Independent Director22.1yrsUS$532.60k0.0045%
$ 745.8k
Christopher Causey
Independent Director21.3yrsUS$481.54k0.0082%
$ 1.4m
Robert Bourge
Member of the Scientific Advisory Boardno dataNessun datoNessun dato
Thomas Thompson
Independent Director22.8yrsUS$456.54k0.050%
$ 8.4m
Magdi Yacoub
Member of the Scientific Advisory Boardno dataNessun datoNessun dato
Judy Olian
Independent Director9.4yrsUS$488.66k0.013%
$ 2.1m
Richard Giltner
Independent Director15.6yrsUS$513.66k0.039%
$ 6.5m

22.2yrs

Durata media

76yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di UTHR è composto da personale esperto e esperto (durata media dell'incarico 22.2 anni).